PW Medtech Group Ltd. (HK:1358)
:1358
Top Page
PW Medtech Group Ltd.
(1358)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$1.50
▲(15.38% Upside)
Action:ReiteratedDate:10/31/25
PW Medtech Group Ltd. is well-positioned with strong financial performance and a solid valuation. The primary concern is the recent decline in cash flow, which needs to be addressed to maintain long-term growth. Technical indicators suggest stable but cautious market sentiment.
Positive Factors
Strong Revenue Growth & Margins
Sustained multi-year revenue expansion and high gross margins indicate durable product demand and pricing power in core medtech offerings. Consistent net income and improving margins support reinvestment capacity and operational resilience over the next several quarters.
Negative Factors
Operating Cash Flow Collapse
A sudden cessation of operating cash inflows signals potential working-capital stress or one-off execution issues that impair cash conversion. Without recovery, the firm may need to draw reserves or curb investment, affecting growth initiatives and financial durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth & Margins
Sustained multi-year revenue expansion and high gross margins indicate durable product demand and pricing power in core medtech offerings. Consistent net income and improving margins support reinvestment capacity and operational resilience over the next several quarters.
Read all positive factors
PW Medtech Group Ltd. (1358) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.68B
Dividend Yield7.46%
Average Volume (3M)1.12M
Price to Earnings (P/E)19.0
Beta (1Y)0.24
Revenue Growth21.39%
EPS Growth-0.57%
CountryHK
Employees1,415
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,473,589,100
10 Day Avg. Volume754,100
30 Day Avg. Volume1,124,400
Financial Highlights & Ratios
PEG Ratio-94.03
Price to Book (P/B)0.37
Price to Sales (P/S)1.89
P/FCF Ratio5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PW Medtech Group Ltd. Business Overview & Revenue Model
Company Description
PW Medtech Group Limited, an investment holding company, operates as a medical device company in the People's Republic of China. The company manufactures and sells infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets,...
How the Company Makes Money
PW Medtech generates revenue primarily through the sale of its medical devices and equipment across its core product lines. The company has established a diversified revenue model comprising direct sales to hospitals and healthcare institutions, a...
PW Medtech Group Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 844.86M | 768.90M | 675.08M | 536.83M | 271.40M | 247.35M |
| Gross Profit | 444.61M | 419.45M | 380.90M | 298.82M | 166.06M | 148.60M |
| EBITDA | 280.13M | 270.97M | 329.48M | 175.49M | 77.98M | 2.94M |
| Net Income | 146.56M | 150.78M | 153.18M | 106.04M | 739.12M | 631.81M |
Balance Sheet | ||||||
| Total Assets | 5.29B | 5.16B | 5.15B | 4.99B | 3.92B | 5.28B |
| Cash, Cash Equivalents and Short-Term Investments | 1.78B | 1.69B | 1.59B | 1.39B | 2.41B | 1.70B |
| Total Debt | 20.28M | 12.07M | 1.13M | 4.24M | 2.44M | 30.46M |
| Total Liabilities | 433.20M | 357.56M | 327.06M | 351.56M | 122.64M | 175.32M |
| Stockholders Equity | 4.00B | 3.97B | 4.04B | 3.95B | 3.79B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | 141.79M | 246.34M | 129.12M | 216.77M | 25.92M | 70.33M |
| Operating Cash Flow | 179.83M | 318.43M | 211.03M | 269.23M | 37.24M | 78.20M |
| Investing Cash Flow | -26.24M | -20.32M | -26.66M | -1.08B | 2.64B | 2.07B |
| Financing Cash Flow | -208.47M | -210.66M | 17.53M | -85.16M | -2.09B | -578.40M |
PW Medtech Group Ltd. Technical Analysis
Negative
1.30
Price Trends
1.21
Negative
1.27
Negative
1.33
Negative
Market Momentum
-0.05
Negative
42.42
Neutral
84.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1358, the sentiment is Negative. The current price of 1.3 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 1.21, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.42 is Neutral, neither overbought nor oversold. The STOCH value of 84.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1358.
PW Medtech Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.68B | 19.04 | 3.68% | 7.46% | 21.39% | -0.57% | |
74 Outperform | HK$6.00B | 8.36 | 16.76% | 3.65% | 6.87% | 18.37% | |
73 Outperform | HK$7.54B | 20.75 | 11.20% | ― | 14.06% | 3.02% | |
68 Neutral | HK$17.14B | 13.02 | 6.64% | 4.58% | 0.74% | 2.13% | |
66 Neutral | HK$13.50B | 45.44 | 4.98% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1358
PW Medtech Group Ltd.
1.14
0.22
23.64%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.79
-1.68
-30.69%
HK:3600
Modern Dental Group Limited
6.42
2.59
67.45%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
35.70
8.60
31.73%
HK:6699
Angelalign Technology Inc.
79.00
31.19
65.24%
PW Medtech Group Ltd. Corporate Events
PW Medtech Resumes Push for Sichuan Ruijian Listing on Beijing Stock Exchange
Dec 30, 2025
PW Medtech Group has provided an update on the planned subsequent listing of its subsidiary Sichuan Ruijian Medical on the Beijing Stock Exchange, a transaction that would constitute a deemed disposal and possible major transaction for the Hong Ko...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.